Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 25Kidney Neoplasms 6Neoplasms 5Neoplasm Metastasis 4Clear-cell metastatic renal cell carcinoma 4Uterine Cervical Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphatic Metastasis 1Lung Neoplasms 1Kidney Diseases 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 45Paclitaxel 42Carboplatin 34Bevacizumab 18Specimen Handling 17Letrozole 16lenvatinib 13Magnetic Resonance Spectroscopy 12dostarlimab 11Cisplatin 11Biopsy 11Taxes 10olaparib 9Fulvestrant 9Doxorubicin 9abemaciclib 8Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Surveys and Questionnaires 5Progestins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Axitinib × 1 year × Clear all
NCT04458259 2026-06-04

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
88 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
106 enrolled 16 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡